What type of study is this?

September 14, 2025

Selected drugs, therapeutic alternatives, and price benchmarks for IPAY 2027 Medicare drug price negotiation.

View Full Paper

Ask AI

Bookmark

Authors

Analysis reveals price benchmarks and therapeutic alternatives for 15 Medicare drugs, suggesting implications for future negotiations.

Price benchmarks, including maximum fair prices, are established for Medicare drugs selected for negotiation.
Analysis identifies therapeutic alternatives for 15 drugs, influencing potential price negotiation outcomes.
The study utilized 2022 Medicare claims data to assess beneficiary drug utilization and clinical indications.
This work enhances transparency in the CMS negotiation processes and benchmarks for Medicare drug pricing.

Sullivan et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark